RE: 2-4% up is this a sign of growing confidence31 Aug 2022 18:29
Aether,
Might be worth digging out the pre-Sprinter result broker notes from Numis and FinnCap. They were projecting bull cases of £75/85 per share at the time and (certainly one of them at least...) went into a fair bit of detail into how they arrived at those figures. Basically based on projected sales/revenue etc.
Obviously the landscape has changed significantly since those heady projections, but the overall objective remains the same for Synairgen: They have to prove the value of their drug. SNG001 could be a world-changing drug - literally the new penicillin - but they will need to prove it beyond all shadow of doubt (hence wanting to get on & pass various trials). They also need to demonstrate how big the market is (or could eventually be) for SNG001.
Basically they need to build a massive portfolio of formidable positive information and data, which makes SNG001 so desperately wanted by big pharmas to add to their own drug portfolios that they won't offer derisory low amounts...or if they do they can be confident that competitors will be sniffing round with bigger offers.
Lots of hoops still left to jump through, but this is the strategy RM spoke to me and Doc83 about at the AGM. Message was that if we cut corners or try to rush to the finish line we won't ever get the full value of the drug. A bit of patience while the pieces of this formidable package of information for the eventual sales-pitch is put together will hopefully reap the financial rewards the drug and investors deserve.
Finally, just remember that £5/share is circa £1bn...or to put it another way, roughly similar to the amount that's down the back of the settee in Pfizer's reception :-)
All IMO, DYOR and GLA!!
Sign In
Follow the stocks
